Morgan Stanley assumed coverage of Ascendis Pharma (ASND) with an Overweight rating and $250 price target The firm is positive on the promising commercial trajectory of Yorvipath in hypoparathyroidism and the compelling opportunities presented by the TransCon pipeline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Ascendis Pharma’s Competitive Edge in Achondroplasia Treatment: Buy Rating Supported by TransCon CNP’s Potential and Yorvipath Launch
- Ascendis Pharma price target raised to $224 from $215 at Oppenheimer
- Ascendis Pharma Grants Employee Warrants to Boost Retention
- Ascendis Pharma’s TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating